November 03, 2025

Get In Touch

Doctors At PGIMER Develop Novel Imaging Modality For Cushing'S Disease Diagnosis

PGIMER Milestone

Chandigarh: PGIMER Achieves Milestone in Medical Imaging

Post Graduate Institute of Medical Education & Research (PGIMER) accomplished another milestone as the Endocrinology Department, in collaboration with the Department of Nuclear Medicine, developed a novel imaging modality for the diagnosis of Cushing's disease.

This technique has been developed for the first time in the world, and PGIMER has already applied for its patent.

About Cushing's Syndrome

Cushing's syndrome is a hormonal disorder that results in:

  • Weight gain with thinning of extremities
  • Hypertension
  • Loss of bone mass
  • Changes in mood like depression
  • Hair loss
  • Striae on the abdomen
  • Bluish patches on the skin

Also Read: Very high degree of negligence is needed for doctors conviction: Bombay HC absolves 3 doctors of IPC 304 A

Once diagnosed, the treatment is rewarding in terms of:

  • Remission of diabetes & hypertension
  • Decrease in weight
  • Improvement in bone strength and mood

Also Read: Nagpur doctor gets 6-month jail after pet dog bites 9-year-old boy

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!